{"id":"r-mini-chop","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Infection"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"R-mini-CHOP is used to treat certain types of non-Hodgkin lymphoma. The addition of rituximab to the CHOP regimen has been shown to improve outcomes in patients with these diseases. The exact mechanism of action of rituximab is not fully understood, but it is thought to work by binding to CD20 on the surface of B cells and marking them for destruction.","oneSentence":"R-mini-CHOP is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:12.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Follicular lymphoma"},{"name":"Diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT05144009","phase":"PHASE2","title":"A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":41},{"nctId":"NCT04332822","phase":"PHASE3","title":"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma","status":"RECRUITING","sponsor":"Nordic Lymphoma Group","startDate":"2020-08-19","conditions":"DLBCL, Diffuse Large B Cell Lymphoma","enrollment":300},{"nctId":"NCT06150053","phase":"","title":"Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL","status":"COMPLETED","sponsor":"University Hospital, Saarland","startDate":"2018-07-01","conditions":"DLBCL, Old Age; Debility","enrollment":79},{"nctId":"NCT05820841","phase":"PHASE3","title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-06-07","conditions":"Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":330},{"nctId":"NCT01087424","phase":"PHASE2","title":"Mini-CHOP and Rituximab in Patients Aged Over 80 Years","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2006-04","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT01148446","phase":"PHASE3","title":"R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2003-01","conditions":"Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-mini-CHOP","genericName":"R-mini-CHOP","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-mini-CHOP is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone. Used for Follicular lymphoma, Diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}